Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia

Jeffrey M. Hoeg, Martha B. Maher, Loren A. Zech, Kent R Bailey, Richard E. Gregg, Karl J. Lackner, Silvia S. Fojo, Michael A. Anchors, Marina Bojanovski, Dennis L. Sprecher, H. Bryan Brewer

Research output: Contribution to journalArticle

71 Scopus citations

Abstract

Patients with low-density lipoprotein (LDL) concentrations in the top 10th percentile of the population (type II hyperlipoproteinemia [HLP]) are at increased risk for premature cardiovascular disease; however, the incidence of myocardial infarction and death can be decreased by LDL cholesterol reduction. Mevinolin, an inhibitor of endogenous cholesterol synthesis, has been shown to reduce LDL cholesterol concentrations in a subset of type II patients with heterozygous familial hypercholesterolemia (FH). Using a double-blind, randomized, crossover, placebo-controlled trial, the safety and efficacy of mevinolin were compared in 24 patients with type II HLP with heterozygous FH (n = 6) or without FH type II HLP (n = 18). Compared with placebo treatment, both apolipoprotein B and LDL cholesterol levels were reduced (p < 0.01) in both FH and non-FH patients by 28 to 34% with mevinolin treatment. In addition, high-density lipoprotein cholesterol levels were significantly increased (p < 0.001) in both patients with FH (16%) and those with non-FH type II HLP (14%). Patients had no serious or clinically significant adverse effects. Thus, mevinolin is a useful drug for treatment of most patients with elevated plasma LDL cholesterol concentrations.

Original languageEnglish (US)
Pages (from-to)933-939
Number of pages7
JournalThe American Journal of Cardiology
Volume57
Issue number11
DOIs
StatePublished - Apr 15 1986
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia'. Together they form a unique fingerprint.

Cite this